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Intradermal rabies vaccine is recommended by the World Health Organisation, but not all countries, including England, follow
this recommendation. A group of 12 adults in England previously given pre-exposure intradermal rabies vaccine were considered
to be non-immune to rabies because their rabies antibody titres were known to be less than 0.5IU/mL. A cohort study
examined the immunizing eﬀect of increasing the participants’ cumulative dose of intradermal rabies to 2.0IU. All patients
subsequentlydemonstratedrabiesantibodylevels>0.5IU·mLsupportingevidenceofadequatesero-conversion.Noadverseeﬀects
of intradermal rabies vaccine boosting were noted. Within the limits of a small study the ﬁndings support the hypothesis that
adequate levels of rabies antibody can be achieved by a schedule of intradermal injections delivered on at least three occasions with
a cumulative rabies vaccine dose of 2.0IU.
1.Introduction
A study undertaken in 2007 on the duration of the immuno-
genicity of intradermal rabies vaccine demonstrated titres of
rabies antibodies consistent with a protective response a
decade or more after immunization with human diploid cell
vaccine [1]. Twenty one of the 89 participants in that study
failed to demonstrate titres of rabies antibodies greater than
0.5IU/mL and were considered not to be adequately pro-
tected against rabies. Of the twenty one, none had received
a cumulative dose of intradermal rabies vaccine greater than
1IU nor had they received rabies intradermal vaccination
on more than two occasions. Based on this observation,
we hypothesised that the production of levels of rabies
antibodies that can be correlated with protective eﬃcacy
requires a minimum cumulative dose of 2.0IU of rabies
vaccine administered intradermally over not less than three
separate occasions. An antibody titre of greater than or equal
to 0.5IU/mL was considered indicative of seroconversion,
providing an adequate titre, in line with the World Health
Organization (WHO) recommendations [2].
The study reported in this paper was undertaken in order
to examine that hypothesis.
2. Method
This study was based on inviting the 21 nonresponding par-
ticipants of the ﬁrst study to provide 4mL blood samples to
conﬁrm the previously determined antibody titres. Twelve of
the 21 were both willing and able to participate. They were
given booster doses by the intradermal route to bring them
up to a life time cumulative dose of 2.0IU of rabies vaccine.
In all cases this proved to require 1.0IU of rabies vaccine.
After an interval of approximately 6 weeks a second 4mL
blood sample was obtained. Antibody levels were measured
from “blinded” blood samples to reduce the risk of bias.
All serum samples were tested by the ﬂuorescent antibody
virus neutralisation test [3]. This test is regarded in the UK
as the gold standard, with a high sensitivity for detecting
postimmunisation antibody levels.2 Advances in Preventive Medicine
Priortothestudycommencingapprovalwassoughtfrom
theHealthProtectionAgency’sResearchSponsorshipReview
Group, the West Yorkshire Primary Care Research and
Development Unit for Research Governance Approval, the
National Research Ethics Service for ethical approval and the
Medicines and Healthcare products Regulatory Agency for
a clinical trial authorization. This approval process com-
menced in August 2008 and concluded in March 2009. The
Eudract Number granted was 2008-005465-56.
Following the protocol developed for this study all 21
possible participants were sent a postal invitation to par-
ticipate in this study. This invitation informed them of the
purpose of the study and what was expected of them. A form
was included on which the possible participant was asked to
indicateiftheywishedtodiscusstakingpartandaskingthem
to provide their preferred contact details. This form could be
returned in an accompanying stamped addressed envelope.
Returned forms were followed up with a telephone call made
by one of the authors to conﬁrm that the participant was still
eligible and willing to participate. Arrangements to collect
the blood samples and to give the booster dose of rabies
vaccinewereagreedbytelephoneandfollowedupinwriting.
In most cases the work was undertaken at the Leeds Overseas
Travellers Clinic, Yorkshire, UK, where the participant had
received their original course of pre-exposure rabies vaccine
prior to travel.
At the ﬁrst of the two clinic visits the participant was
again advised about the study and asked to sign a consent
form. A 4mL venous blood sample was taken and collected
in a plain glass tube and stored at 4◦C. Two separate
0.5IU doses of rabies vaccine were then administered by the
intradermal route over the left deltoid muscle, the injections
being between 2 and 3cms apart. The vaccine used was
Verorab (Pasteur Merieux) Lot number B0529, due to expire
in May 2010. This vaccine is recommended for intradermal
use by WHO [4]. Verorab is prepared using a cell culture
techniqueusingcellsoriginallyharvestedfromAfricanGreen
Monkeys. All blood was collected by one of the authors
who also gave all the intradermal immunizations to ensure
consistency of technique. After an interval of six to eight
weeks participants were seen again. Enquiries were made
a b o u ta n yp o s s i b l es i d ee ﬀects from the immunization, and
a second 4mL venous blood sample was collected. Antibody
results were matched against the list of participants to allow
tabulation and review.
3.SubjectsandRecruitment
The only people initially eligible to participate were the 21
participants from the previous study who had demonstrated
antibody titres less than 0.5IU/mL. Five people did not reply
to the letter of invitation and could not be traced. Two had
contraindications to participation in the form of additional
intramuscular doses of rabies vaccine to protect them during
travel to rabies risk areas during the two years since the ﬁrst
study. One had developed a serious illness and was now
taking long-term steroids. Only one previous participant
expressly refused to participate in this study.
Twelve previous participants agreed to take part again
and on questioning did not appear to have any contra-
indication from doing so. No ﬁnancial inducement was paid
to the participants. All participants were, however, assured
that if any problem did arise as a result of their participation
therewasahelplinetelephonenumbertocall.Theywerealso
informed in writing that the researchers were indemniﬁed
should there be any serious untoward consequences from
participation. The eligibility criteria used were participation
in the previous study, having a documented antibody titre of
less than 0.5IU/mL, not having received any rabies vaccine
by any route since the ﬁrst study, and not having any condi-
tion that might impair immunity.
4. Outcome Measures
The main outcome measure sought was the rabies anti-
body titre following the booster dose of rabies vaccine.
A secondary outcome measure was the degree of change
in antibody titre since the previous study. Participants were
also all asked if they experienced any untoward eﬀects of the
booster dose.
5.StatisticalAnalysis
Laboratory results were tabulated. The key determination
was the proportion of participants who, following booster
intradermal rabies vaccine demonstrated antibody titres
equal to or greater than 0.5IU/mL. The mean rise in anti-
body titre was also determined and examined for the eﬀects
of age or gender.
6. Results and Discussion
The key results are displayed in Table 1.
Of the 12 participants the majority (75%) were women.
Ages ranged from 20 to 71 years of age. All had received
a total of 0.4mL of previously available vaccines which is
equivalent to 1IU of rabies vaccine. Six of the 12 participants
had received their previous rabies vaccine at a single clinic
visit, ﬁve on two clinic visits, and one on four clinic
visits. As shown in Table 1 pre-booster antibody titres are
consistent with the previous estimation two years earlier. All
participantsdemonstratedpostboosterantibodytitreshigher
than the minimum considered consistent with immunity
to rabies. The mean pre-booster titre was 0.18 (CI 0.12–
0.25), and the mean postbooster titre was 17.33 (CI1.48–
33.19). The mean antibody rise was 17.15IU/mL. The
range of antibody rises was very wide, varying from 1.75
to 69.93IU/mL. The 95% conﬁdence intervals are 1.326–
32.973IU/mL.
The two results with increases in antibody titre of almost
70 skew the results and lie outside the 95% conﬁdence inter-
vals. Using a log transformation of the diﬀerence between
pre- and posttitre levels gives a highly signiﬁcant P value
of <.01; the post-booster titre levels were signiﬁcantly larger
than the pre-booster titre levels (see Figure 1).Advances in Preventive Medicine 3
Table 1: Summary of the results obtained for each participant.
Participant
number Age Gender Year last
immunised
Vaccine
administered on
days
Antibody titre
in 2007
Pre-booster
titre, 2009
Post-booster
titre, 2009
Rise in antibody
titre following
immunisation
1 38 F 2003 0, 54 0.38 0.13 7.79 7.66
2 66 F 2000 0, 28 0.38 0.29 3.42 3.13
3 32 F 2002 0 0.06 0.07 5.92 5.85
4 67 M 2004 0 0.29 0.07 3.42 3.35
5 71 M 2003 0, 28 0.38 0.22 1.97 1.75
6 45 F 1998 0, 28 0.22 0.13 2.60 2.47
7 36 F 2003 0 0.38 0.29 13.5 13.21
8 30 F 2004 0 0.29 0.22 70.15 69.93
9 39 F 2005 0, 28 0.38 0.38 70.15 69.77
10 34 F 2002 0, 7, 21, 28 0.38 0.13 7.79 7.66
11 20 M 1999 0 0.38 0.17 7.79 7.62
12 28 F 2005 0 0.38 0.10 13.5 13.4
All titre results expressed in IU/mL.
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Figure 1: Scatter plot of antibody titre rise and age in years.
The most notable increases in antibody titre were ob-
served in two women in their 30s who had received their last
rabies immunization between 4 and 5 years previously.Apart
from age and gender no explanation for their high antibody
response was determined. If these two results are excluded,
the results did not show any obvious gender diﬀerence.
The apparent decline in antibody response with age is
shown even if the two outliers are removed from the analysis
as shown in Figure 2.
Figure 3 suggests that there was a decline in antibody
response after 10 years. The titre immediately prior to boost-
ing did not appear to have any direct eﬀect on the titre
achieved after boosting immunization. This can be observed
in Figure 4.
Participant 2 disclosed after the second blood sample
that she had received chemotherapy for breast cancer since
the previous study, if this had been disclosed earlier, she
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Figure 2: Scatter plot of rise in tire after boosting with outliers
removed against age.
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Figure 3: Scatter plot of rise in antibody titre and year last
immunized.
would have been excluded from the study. Interestingly, she
demonstrated a good antibody response to the intrader-
mal immunization. None of the participants reported any
noticeable side eﬀects from the immunization. None of the
participants called the telephone helpline oﬀered at entry
to the study. Rabies remains a serious global challenge with
an estimated 55,000 deaths each year [5]. The availability of4 Advances in Preventive Medicine
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Figure 4: Scatter plot of pre-booster tire and fold rise in titre after
boosting.
an eﬀective vaccine is restricted by total vaccine production
and relatively high cost. If intradermal rabies immunization
schedules were introduced for pre-exposure prophylaxis, it
would both increase the global supply of vaccine doses and
reduce the cost per person immunised.
It is not possible to accurately determine the level of
rabies virus neutralizing antibody adequate to provide pro-
tective immunity for humans. The World Health Organiza-
tion regards 0.5IU/mL as an adequate level of antibody after
vaccination [2] and that has been accepted by the authors
of this paper, providing the basis for our conﬁdence that 12
previously inadequately protected individuals now have ade-
quate protective antibody levels. Previous work undertaken
by the authors suggests that this protection should last for at
least ten years [1].
Versions of rabies vaccine previously used on the patients
in this study contained 2.5IU/mL. Many previous reports
that discuss the eﬀectiveness of both intramuscular and
intradermal vaccines quote the dose administered in volume
terms. The vaccine available for this study, Verorab, has twice
the concentration containing 5IU/mL, which is supplied
in 0.5mL vials each containing 2.5IU of rabies vaccine. In
order to avoid confusion this paper has quoted the dose in
International Units rather than volume administered.
There were only 12 participants in this study so there is
a possibility that they do not represent the true population
of responders to boosting with intradermal vaccine. Calcu-
lation of the 95% conﬁdence intervals of a small sample
with a skewed distribution results, as in this case, in wide
conﬁdence intervals. Participants ranged widely in age and
in time since previous rabies immunization. All developed
an eﬀective rabies antibody response. All 12 participants in
thisstudydemonstratedagoodresponsetotheboosterdoses
supporting the hypothesis that antibody levels consistent
with immunity to rabies are likely to be achieved if a total of
2IU of rabies vaccine have been administered over three or
more occasions. In this study the last dose had been adminis-
tered within the previous 10 years. Taken with the ﬁndings of
long-lasting immunity following intradermal rabies vaccine
in our earlier study [1], there is evidence to support a pre-
exposure intradermal rabies immunization schedule based
on delivering 2.0IU spread over three doses. The interval
between these three initial doses could be based on the
observations of Thai studies which demonstrated eﬀective
protection with doses given on days 0, 7, and 28 described
by Strady et al. [6] who used the intramuscular route and
Kamoltham et al. [7] who used puriﬁed chick embryo
cell vaccine given intradermally. A study by Naraporn et
al. [8] examined the immune response to rabies booster
immunization after an interval of 5 years and showed that
all 36 patients who completed the study at 28 days had
a good anamnestic antibody response to two intradermal
booster injections of puriﬁed duck embryo cell vaccine
given 3 days apart. Malerczyk et al. [9] report a study in
15Germanveterinarianswhohadreceivedpuriﬁedchickcell
embryo cell vaccine 14 years previously who were boosted
with intramuscular puriﬁed chick cell embryo vaccine.
All ten veterinarians who submitted blood samples after
immunization demonstrated a good anamnestic response.
Suwansrinonetal.[10]describeastudyinThailandinwhich
53 patients who had received rabies immunization between
10 and 20 years previously were given two 0.9IU doses
of Vero cell rabies vaccine three days apart. Two weeks
after immunization all had antibody levels that exceeded the
critical threshold considered to provide adequate immunity
of 0.5IU/mL.
The use of intradermal human diploid cell rabies vaccine
for boosting purposes was examined in a study undertaken
in 1987 which followed up 40 laboratory workers who had
been given intradermal rabies vaccine in 3 separate doses
totaling 0.75IU [11]. Twenty of these workers demonstrated
titres considered to be protective at 1 year, but by 2 years
5 were considered to have unprotective levels. Intradermal
boosters given to 4 of these 5 laboratory workers produced
high titres of rabies antibody. That study recommended
s e r o l o g i c a lt e s t i n ge v e r yt w oy e a r sw i t hab o o s t e rd o s eg i v e n
to those with what are regarded as unprotective titre levels.
The observations of the study being reported in this
report suggest that increasing the initial course to a total of
2IU given over three clinic visits will provide eﬀective rabies
protection. Review of the literature and our previous study
suggest that adequate immunity will be maintained for at
least 10 years without the need for expensive serological test-
ing or boosting. It is reasonable to conclude that immuniza-
tion with at least 2IU of rabies vaccine by the intradermal
route should result in an antibody titre that will provide
protection. This regimen could preserve the limited stocks
of rabies biologicals, including rabies immunoglobulin. It is
suggested that the time intervals used between doses can be
based on the work of Strady et al. [6], with an initial dose
of 1IU on day 0 followed by 0.5IU on days 7 and 28. These
doses are relatively easy to translate into volume terms based
on the concentration of the vaccine available for use.
No adverse eﬀects were reported after immunization
supporting the hypothesis that boosters of two intradermal
0.5IU Vero cell-derived rabies vaccine injections can safely
be coadministered after 10 years with immunity maintained
at an adequate level.
This study did not examine the eﬀect of giving a single
0.5IU dose of rabies vaccine as a 10-yearly booster; however
the good level of response suggests that further cost and
vaccine savings could be safely achieved. Further research toAdvances in Preventive Medicine 5
assess the increase in antibody titre following a single 0.5IU
dose of rabies vaccine is advisable. The absence of any
serious side eﬀects in this small sample of 12 patients given
intradermal rabies vaccine is reassuring and helps to give
conﬁdence that the intradermal immunization route is not
only eﬀective but also safe [5].
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